Skip to main content
Equibles
MTVA logo

MTVA · MetaVia Inc. · Metrics

Track MTVA — free

Use MTVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MTVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.43 +0.34 (+31.19%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Due in large part to the ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these unaudited condensed consolidated financial statements.”
View the 10-Q filed Aug 6, 2026
Market Cap
$7.18M
Shares
6.59M
Volume · Nov 6 968.62K Avg daily vol (3M) 109.5K

MTVA metrics

51 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.43
Market cap
$7.18M

Price action

23 metrics
Price change (1W)
-8.4%
Price change (30D)
-25.3%
Price change (3M)
-24.8%
Price change (6M)
-18.0%
Price change (YTD)
-87.1%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
152.1%
Annualized volatility (3M)
73.3%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.0
RSI (14D)
37.2
Price vs SMA 50
-27.1%
Price vs SMA 200
-33.5%
Avg volume (3M)
95,173
Relative volume
11.4
Average dollar volume
$137,544

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
6.59M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 95.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-201.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-01-01

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$14.93M
Net income (TTM)
−$14.45M
Trailing 12 months
Diluted EPS (TTM)
$-2.24
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.31

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+326.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-211.8%
Return on assets
-108.9%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$12.63M
Latest balance sheet
Cash & equivalents
$12.63M
Total assets
$13.27M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$15.84M
Capital expenditures (TTM)
—
R&D (TTM)
$7.73M
SG&A (TTM)
—
Stock compensation (TTM)
$398,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
17
13F filer change QoQ
+5
Institutional ownership
4.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.4%
Private-fund adviser ownership
1.2%
Active holders' share change QoQ
+963.3%
Holder tenure
2.0
Price vs estimated holder cost
-25.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
1.5%
Latest settlement · 1.5 days to cover
Days to cover
1.5d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1638287 CUSIP 64132R503 13F (30d) 4 filings 4 filers Visit website Investor relations